Selective inhibitors of protein methyltransferases

Journal of Medicinal Chemistry

Volumn 58, Issue 4, 2015, Pages 1596-1629

  Kaniskan, H Ümit ^a   Konze, Kyle D ^a   Jin, Jian ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; HISTONE METHYLTRANSFERASE; LYSINE; METHYLTRANSFERASE INHIBITOR; MULTIPROTEIN COMPLEX; PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN METHYLTRANSFERASE; TRANSCRIPTION FACTOR EZH2; ENZYME INHIBITOR; METHYLTRANSFERASE; MOLECULAR LIBRARY;

ARTICLE; CHROMATIN; CRYSTAL STRUCTURE; DRUG DEVELOPMENT; DRUG STRUCTURE; DRUG TARGETING; GENE EXPRESSION; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN METHYLATION; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ENZYME INHIBITORS; HUMANS; METHYLTRANSFERASES; MODELS, MOLECULAR; MOLECULAR CONFORMATION; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84923899867     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501234a     Document Type: Article

References (290)

1. Bernstein, B. E.; Meissner, A.; Lander, E. S. The mammalian epigenome Cell 2007, 128, 669-681
2. Jones, P. A.; Baylin, S. B. The epigenomics of cancer Cell 2007, 128, 683-692
3. Berger, S. L.; Kouzarides, T.; Shiekhattar, R.; Shilatifard, A. An operational definition of epigenetics Genes Dev. 2009, 23, 781-783
4. Luger, K.; Mader, A. W.; Richmond, R. K.; Sargent, D. F.; Richmond, T. J. Crystal structure of the nucleosome core particle at 2.8 Å resolution Nature 1997, 389, 251-260
5. Khorasanizadeh, S. The nucleosome: from genomic organization to genomic regulation Cell 2004, 116, 259-272
6. Kouzarides, T. Chromatin modifications and their function Cell 2007, 128, 693-705
7. Allis, C. D.; Jenuwein, T.; Reinberg, D. Epigenetics; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 2007; p 502.
8. Gelato, K. A.; Fischle, W. Role of histone modifications in defining chromatin structure and function Biol. Chem. 2008, 389, 353-363
9. Strahl, B. D.; Allis, C. D. The language of covalent histone modifications Nature 2000, 403, 41-45
10. Jenuwein, T.; Allis, C. D. Translating the histone code Science 2001, 293, 1074-1080
11. Arrowsmith, C. H.; Bountra, C.; Fish, P. V.; Lee, K.; Schapira, M. Epigenetic protein families: a new frontier for drug discovery Nat. Rev. Drug Discovery 2012, 11, 384-400
12. Copeland, R. A.; Solomon, M. E.; Richon, V. M. Protein methyltransferases as a target class for drug discovery Nat. Rev. Drug Discovery 2009, 8, 724-732
13. Lyko, F.; Brown, R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies J. Natl. Cancer Inst. 2005, 97, 1498-1506
14. Duvic, M.; Vu, J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma Expert Opin. Invest. Drugs 2007, 16, 1111-1120
15. Szyf, M. Epigenetics, DNA methylation, and chromatin modifying drugs Annu. Rev. Pharmacol. Toxicol. 2009, 49, 243-263
16. Liu, Y.; Liu, K.; Qin, S.; Xu, C.; Min, J. Epigenetic targets and drug discovery: Part 1: Histone methylation Pharmacol. Ther. 2014, 143, 275-294
17. Sweis, R. F.; Michaelides, M. R. Recent advances in small-molecule modulation of epigenetic targets: discovery and development of histone methyltransferase and bromodomain inhibitors Annu. Rep. Med. Chem. 2013, 48, 185-203
18. Wang, Z.; Patel, D. J. Small molecule epigenetic inhibitors targeted to histone lysine methyltransferases and demethylases Q. Rev. Biophys. 2013, 46, 349-373
19. Zagni, C.; Chiacchio, U.; Rescifina, A. Histone methyltransferase inhibitors: novel epigenetic agents for cancer treatment Curr. Med. Chem. 2013, 20, 167-185
20. Helin, K.; Dhanak, D. Chromatin proteins and modifications as drug targets Nature 2013, 502, 480-488
21. He, Y.; Korboukh, I.; Jin, J.; Huang, J. Targeting protein lysine methylation and demethylation in cancers Acta Biochim. Biophys. Sin. 2012, 44, 70-79
22. Yost, J. M.; Korboukh, I.; Liu, F.; Gao, C.; Jin, J. Targets in epigenetics: inhibiting the methyl writers of the histone code Curr. Chem. Genomics 2011, 5, 72-84
23. Bissinger, E.-M.; Heinke, R.; Sippl, W.; Jung, M. Targeting epigenetic modifiers: inhibitors of histone methyltransferases MedChemComm 2010, 1, 114-124
24. Spannhoff, A.; Sippl, W.; Jung, M. Cancer treatment of the future: inhibitors of histone methyltransferases Int. J. Biochem. Cell Biol. 2009, 41, 4-11
25. Spannhoff, A.; Hauser, A. T.; Heinke, R.; Sippl, W.; Jung, M. The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors ChemMedChem. 2009, 4, 1568-1582
26. Martin, C.; Zhang, Y. The diverse functions of histone lysine methylation Nat. Rev. Mol. Cell Biol. 2005, 6, 838-849
27. Shi, X.; Kachirskaia, I.; Yamaguchi, H.; West, L. E.; Wen, H.; Wang, E. W.; Dutta, S.; Appella, E.; Gozani, O. Modulation of p53 function by SET8-mediated methylation at lysine 382 Mol. Cell 2007, 27, 636-646
28. Chuikov, S.; Kurash, J. K.; Wilson, J. R.; Xiao, B.; Justin, N.; Ivanov, G. S.; McKinney, K.; Tempst, P.; Prives, C.; Gamblin, S. J.; Barlev, N. A.; Reinberg, D. Regulation of p53 activity through lysine methylation Nature 2004, 432, 353-360
29. Jenuwein, T.; Laible, G.; Dorn, R.; Reuter, G. SET domain proteins modulate chromatin domains in eu- and heterochromatin Cell. Mol. Life Sci. 1998, 54, 80-93
30. Baumbusch, L. O.; Thorstensen, T.; Krauss, V.; Fischer, A.; Naumann, K.; Assalkhou, R.; Schulz, I.; Reuter, G.; Aalen, R. B. The Arabidopsis thaliana genome contains at least 29 active genes encoding SET domain proteins that can be assigned to four evolutionarily conserved classes Nucleic Acids Res. 2001, 29, 4319-4333
31. Cheng, X.; Collins, R. E.; Zhang, X. Structural and sequence motifs of protein (histone) methylation enzymes Annu. Rev. Biophys. Biomol. Struct. 2005, 34, 267-294
32. Jacobs, S. A.; Harp, J. M.; Devarakonda, S.; Kim, Y.; Rastinejad, F.; Khorasanizadeh, S. The active site of the SET domain is constructed on a knot Nat. Struct. Biol. 2002, 9, 833-838
33. Kouzarides, T. Histone methylation in transcriptional control Curr. Opin. Genet. Dev. 2002, 12, 198-209
34. Allis, C. D.; Berger, S. L.; Cote, J.; Dent, S.; Jenuwien, T.; Kouzarides, T.; Pillus, L.; Reinberg, D.; Shi, Y.; Shiekhattar, R.; Shilatifard, A.; Workman, J.; Zhang, Y. New nomenclature for chromatin-modifying enzymes Cell 2007, 131, 633-636
35. Zhang, X.; Tamaru, H.; Khan, S. I.; Horton, J. R.; Keefe, L. J.; Selker, E. U.; Cheng, X. Structure of the neurospora SET domain protein DIM-5, a histone H3 lysine methyltransferase Cell 2002, 111, 117-127
36. Taverna, S. D.; Li, H.; Ruthenburg, A. J.; Allis, C. D.; Patel, D. J. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers Nat. Struct. Mol. Biol. 2007, 14, 1025-1040
37. Bannister, A. J.; Kouzarides, T. Regulation of chromatin by histone modifications Cell Res. 2011, 21, 381-395
38. Barski, A.; Cuddapah, S.; Cui, K.; Roh, T. Y.; Schones, D. E.; Wang, Z.; Wei, G.; Chepelev, I.; Zhao, K. High-resolution profiling of histone methylations in the human genome Cell 2007, 129, 823-837
39. Zhang, Z.; Pugh, B. F. High-resolution genome-wide mapping of the primary structure of chromatin Cell 2011, 144, 175-186
40. Krauss, V. Glimpses of evolution: heterochromatic histone H3K9 methyltransferases left its marks behind Genetica 2008, 133, 93-106
41. Bannister, A. J.; Zegerman, P.; Partridge, J. F.; Miska, E. A.; Thomas, J. O.; Allshire, R. C.; Kouzarides, T. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain Nature 2001, 410, 120-124
42. Chen, M. W.; Hua, K. T.; Kao, H. J.; Chi, C. C.; Wei, L. H.; Johansson, G.; Shiah, S. G.; Chen, P. S.; Jeng, Y. M.; Cheng, T. Y.; Lai, T. C.; Chang, J. S.; Jan, Y. H.; Chien, M. H.; Yang, C. J.; Huang, M. S.; Hsiao, M.; Kuo, M. L. H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM Cancer Res. 2010, 70, 7830-7840
43. Wen, B.; Wu, H.; Shinkai, Y.; Irizarry, R. A.; Feinberg, A. P. Large histone H3 lysine 9 dimethylated chromatin blocks distinguish differentiated from embryonic stem cells Nat. Genet. 2009, 41, 246-250
44. Kang, M. Y.; Lee, B. B.; Kim, Y. H.; Chang, D. K.; Kyu Park, S.; Chun, H. K.; Song, S. Y.; Park, J.; Kim, D. H. Association of the SUV39H1 histone methyltransferase with the DNA methyltransferase 1 at mRNA expression level in primary colorectal cancer Int. J. Cancer 2007, 121, 2192-2197
45. Kondo, Y.; Shen, L.; Ahmed, S.; Boumber, Y.; Sekido, Y.; Haddad, B. R.; Issa, J. P. Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells PLoS One 2008, 3, e2037
46. Watanabe, H.; Soejima, K.; Yasuda, H.; Kawada, I.; Nakachi, I.; Yoda, S.; Naoki, K.; Ishizaka, A. Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells Cancer Cell Int. 2008, 8, 15
47. Imai, K.; Togami, H.; Okamoto, T. Involvement of histone H3 lysine 9 (H3K9) methyl transferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294 J. Biol. Chem. 2010, 285, 16538-16545
48. Maze, I.; Covington, H. E., III; Dietz, D. M.; LaPlant, Q.; Renthal, W.; Russo, S. J.; Mechanic, M.; Mouzon, E.; Neve, R. L.; Haggarty, S. J.; Ren, Y.; Sampath, S. C.; Hurd, Y. L.; Greengard, P.; Tarakhovsky, A.; Schaefer, A.; Nestler, E. J. Essential role of the histone methyltransferase G9a in cocaine-induced plasticity Science 2010, 327, 213-216
49. Rea, S.; Eisenhaber, F.; OCarroll, D.; Strahl, B. D.; Sun, Z. W.; Schmid, M.; Opravil, S.; Mechtler, K.; Ponting, C. P.; Allis, C. D.; Jenuwein, T. Regulation of chromatin structure by site-specific histone H3 methyltransferases Nature 2000, 406, 593-599
50. Aagaard, L.; Laible, G.; Selenko, P.; Schmid, M.; Dorn, R.; Schotta, G.; Kuhfittig, S.; Wolf, A.; Lebersorger, A.; Singh, P. B.; Reuter, G.; Jenuwein, T. Functional mammalian homologues of the Drosophila PEV-modifier Su(var)3-9 encode centromere-associated proteins which complex with the heterochromatin component M31 EMBO J. 1999, 18, 1923-1938
51. Peters, A. H.; OCarroll, D.; Scherthan, H.; Mechtler, K.; Sauer, S.; Schofer, C.; Weipoltshammer, K.; Pagani, M.; Lachner, M.; Kohlmaier, A.; Opravil, S.; Doyle, M.; Sibilia, M.; Jenuwein, T. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability Cell 2001, 107, 323-337
52. Brasher, S. V.; Smith, B. O.; Fogh, R. H.; Nietlispach, D.; Thiru, A.; Nielsen, P. R.; Broadhurst, R. W.; Ball, L. J.; Murzina, N. V.; Laue, E. D. The structure of mouse HP1 suggests a unique mode of single peptide recognition by the shadow chromo domain dimer EMBO J. 2000, 19, 1587-1597
53. Muramatsu, D.; Singh, P. B.; Kimura, H.; Tachibana, M.; Shinkai, Y. Pericentric heterochromatin generated by HP1 protein interaction-defective histone methyltransferase Suv39h1 J. Biol. Chem. 2013, 288, 25285-25296
54. Nielsen, S. J.; Schneider, R.; Bauer, U. M.; Bannister, A. J.; Morrison, A.; OCarroll, D.; Firestein, R.; Cleary, M.; Jenuwein, T.; Herrera, R. E.; Kouzarides, T. Rb targets histone H3 methylation and HP1 to promoters Nature 2001, 412, 561-565
55. Kirschmann, D. A.; Lininger, R. A.; Gardner, L. M.; Seftor, E. A.; Odero, V. A.; Ainsztein, A. M.; Earnshaw, W. C.; Wallrath, L. L.; Hendrix, M. J. Down-regulation of HP1Hsalpha expression is associated with the metastatic phenotype in breast cancer Cancer Res. 2000, 60, 3359-3363
56. Brasacchio, D.; Okabe, J.; Tikellis, C.; Balcerczyk, A.; George, P.; Baker, E. K.; Calkin, A. C.; Brownlee, M.; Cooper, M. E.; El-Osta, A. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail Diabetes 2009, 58, 1229-1236
57. Spyropoulou, A.; Gargalionis, A.; Dalagiorgou, G.; Adamopoulos, C.; Papavassiliou, K. A.; Lea, R. W.; Piperi, C.; Papavassiliou, A. G. Role of histone lysine methyltransferases SUV39H1 and SETDB1 in gliomagenesis: modulation of cell proliferation, migration, and colony formation NeuroMol. Med. 2014, 16, 70-82
58. Greiner, D.; Bonaldi, T.; Eskeland, R.; Roemer, E.; Imhof, A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9 Nat. Chem. Biol. 2005, 1, 143-145
59. Gardiner, D. M.; Waring, P.; Howlett, B. J. The epipolythiodioxopiperazine (ETP) class of fungal toxins: distribution, mode of action, functions and biosynthesis Microbiology 2005, 151, 1021-1032
60. Iwasa, E.; Hamashima, Y.; Fujishiro, S.; Higuchi, E.; Ito, A.; Yoshida, M.; Sodeoka, M. Total synthesis of (+)-chaetocin and its analogues: their histone methyltransferase G9a inhibitory activity J. Am. Chem. Soc. 2010, 132, 4078-4079
61. Fujishiro, S.; Dodo, K.; Iwasa, E.; Teng, Y.; Sohtome, Y.; Hamashima, Y.; Ito, A.; Yoshida, M.; Sodeoka, M. Epidithiodiketopiperazine as a pharmacophore for protein lysine methyltransferase G9a inhibitors: reducing cytotoxicity by structural simplification Bioorg. Med. Chem. Lett. 2013, 23, 733-736
62. Cherblanc, F. L.; Chapman, K. L.; Brown, R.; Fuchter, M. J. Chaetocin is a nonspecific inhibitor of histone lysine methyltransferases Nat. Chem. Biol. 2013, 9, 136-137
63. Greiner, D.; Bonaldi, T.; Eskeland, R.; Roemer, E.; Imhof, A. Reply to "Chaetocin is a nonspecific inhibitor of histone lysine methyltransferases" Nat. Chem. Biol. 2013, 9, 137
64. Cherblanc, F. L.; Chapman, K. L.; Reid, J.; Borg, A. J.; Sundriyal, S.; Alcazar-Fuoli, L.; Bignell, E.; Demetriades, M.; Schofield, C. J.; DiMaggio, P. A., Jr.; Brown, R.; Fuchter, M. J. On the histone lysine methyltransferase activity of fungal metabolite chaetocin J. Med. Chem. 2013, 56, 8616-8625
65. Tachibana, M.; Sugimoto, K.; Nozaki, M.; Ueda, J.; Ohta, T.; Ohki, M.; Fukuda, M.; Takeda, N.; Niida, H.; Kato, H.; Shinkai, Y. G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis Genes Dev. 2002, 16, 1779-1791
66. Tachibana, M.; Ueda, J.; Fukuda, M.; Takeda, N.; Ohta, T.; Iwanari, H.; Sakihama, T.; Kodama, T.; Hamakubo, T.; Shinkai, Y. Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3-K9 Genes Dev. 2005, 19, 815-826
67. Rathert, P.; Dhayalan, A.; Murakami, M.; Zhang, X.; Tamas, R.; Jurkowska, R.; Komatsu, Y.; Shinkai, Y.; Cheng, X.; Jeltsch, A. Protein lysine methyltransferase G9a acts on non-histone targets Nat. Chem. Biol. 2008, 4, 344-346
68. Huang, J.; Dorsey, J.; Chuikov, S.; Zhang, X.; Jenuwein, T.; Reinberg, D.; Berger, S. L. G9A and GLP methylate lysine 373 in the tumor suppressor p53 J. Biol. Chem. 2010, 285, 9636-9641
69. Kondo, Y.; Shen, L.; Suzuki, S.; Kurokawa, T.; Masuko, K.; Tanaka, Y.; Kato, H.; Mizuno, Y.; Yokoe, M.; Sugauchi, F.; Hirashima, N.; Orito, E.; Osada, H.; Ueda, R.; Guo, Y.; Chen, X.; Issa, J. P.; Sekido, Y. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas Hepatol. Res. 2007, 37, 974-983
70. Goyama, S.; Nitta, E.; Yoshino, T.; Kako, S.; Watanabe-Okochi, N.; Shimabe, M.; Imai, Y.; Takahashi, K.; Kurokawa, M. EVI-1 interacts with histone methyltransferases SUV39H1 and G9a for transcriptional repression and bone marrow immortalization Leukemia 2010, 24, 81-88
71. Lehnertz, B.; Pabst, C.; Su, L.; Miller, M.; Liu, F.; Yi, L.; Zhang, R.; Krosl, J.; Yung, E.; Kirschner, J.; Rosten, P.; Underhill, T. M.; Jin, J.; Hebert, J.; Sauvageau, G.; Humphries, R. K.; Rossi, F. M. The methyltransferase G9a regulates HoxA9-dependent transcription in AML Genes Dev. 2014, 28, 317-327
72. Oh, S. T.; Kim, K. B.; Chae, Y. C.; Kang, J. Y.; Hahn, Y.; Seo, S. B. H3K9 histone methyltransferase G9a-mediated transcriptional activation of p21 FEBS Lett. 2014, 588, 685-691
73. Covington, H. E., III; Maze, I.; Sun, H.; Bomze, H. M.; DeMaio, K. D.; Wu, E. Y.; Dietz, D. M.; Lobo, M. K.; Ghose, S.; Mouzon, E.; Neve, R. L.; Tamminga, C. A.; Nestler, E. J. A role for repressive histone methylation in cocaine-induced vulnerability to stress Neuron 2011, 71, 656-670
74. Schaefer, A.; Sampath, S. C.; Intrator, A.; Min, A.; Gertler, T. S.; Surmeier, D. J.; Tarakhovsky, A.; Greengard, P. Control of cognition and adaptive behavior by the GLP/G9a epigenetic suppressor complex Neuron 2009, 64, 678-691
75. Link, P. A.; Gangisetty, O.; James, S. R.; Woloszynska-Read, A.; Tachibana, M.; Shinkai, Y.; Karpf, A. R. Distinct roles for histone methyltransferases G9a and GLP in cancer germ-line antigen gene regulation in human cancer cells and murine embryonic stem cells Mol. Cancer Res. 2009, 7, 851-862
76. Tachibana, M.; Matsumura, Y.; Fukuda, M.; Kimura, H.; Shinkai, Y. G9a/GLP complexes independently mediate H3K9 and DNA methylation to silence transcription EMBO J. 2008, 27, 2681-2690
77. Dong, K. B.; Maksakova, I. A.; Mohn, F.; Leung, D.; Appanah, R.; Lee, S.; Yang, H. W.; Lam, L. L.; Mager, D. L.; Schubeler, D.; Tachibana, M.; Shinkai, Y.; Lorincz, M. C. DNA methylation in ES cells requires the lysine methyltransferase G9a but not its catalytic activity EMBO J. 2008, 27, 2691-2701
78. Shi, Y.; Desponts, C.; Do, J. T.; Hahm, H. S.; Scholer, H. R.; Ding, S. Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds Cell Stem Cell 2008, 3, 568-574
79. Shi, Y.; Do, J. T.; Desponts, C.; Hahm, H. S.; Scholer, H. R.; Ding, S. A combined chemical and genetic approach for the generation of induced pluripotent stem cells Cell Stem Cell 2008, 2, 525-528
80. Chen, X.; Skutt-Kakaria, K.; Davison, J.; Ou, Y. L.; Choi, E.; Malik, P.; Loeb, K.; Wood, B.; Georges, G.; Torok-Storb, B.; Paddison, P. J. G9a/GLP-dependent histone H3K9me2 patterning during human hematopoietic stem cell lineage commitment Genes Dev. 2012, 26, 2499-2511
81. Antignano, F.; Burrows, K.; Hughes, M. R.; Han, J. M.; Kron, K. J.; Penrod, N. M.; Oudhoff, M. J.; Wang, S. K.; Min, P. H.; Gold, M. J.; Chenery, A. L.; Braam, M. J.; Fung, T. C.; Rossi, F. M.; McNagny, K. M.; Arrowsmith, C. H.; Lupien, M.; Levings, M. K.; Zaph, C. Methyltransferase G9A regulates T cell differentiation during murine intestinal inflammation J. Clin. Invest. 2014, 124, 1945-1955
82. Kleefstra, T.; Brunner, H. G.; Amiel, J.; Oudakker, A. R.; Nillesen, W. M.; Magee, A.; Genevieve, D.; Cormier-Daire, V.; van Esch, H.; Fryns, J. P.; Hamel, B. C.; Sistermans, E. A.; de Vries, B. B.; van Bokhoven, H. Loss-of-function mutations in euchromatin histone methyl transferase 1 (EHMT1) cause the 9q34 subtelomeric deletion syndrome Am. J. Hum. Genet. 2006, 79, 370-377
83. Kleefstra, T.; van Zelst-Stams, W. A.; Nillesen, W. M.; Cormier-Daire, V.; Houge, G.; Foulds, N.; van Dooren, M.; Willemsen, M. H.; Pfundt, R.; Turner, A.; Wilson, M.; McGaughran, J.; Rauch, A.; Zenker, M.; Adam, M. P.; Innes, M.; Davies, C.; Lopez, A. G.; Casalone, R.; Weber, A.; Brueton, L. A.; Navarro, A. D.; Bralo, M. P.; Venselaar, H.; Stegmann, S. P.; Yntema, H. G.; van Bokhoven, H.; Brunner, H. G. Further clinical and molecular delineation of the 9q subtelomeric deletion syndrome supports a major contribution of EHMT1 haploinsufficiency to the core phenotype J. Med. Genet. 2009, 46, 598-606
84. Ohno, H.; Shinoda, K.; Ohyama, K.; Sharp, L. Z.; Kajimura, S. EHMT1 controls brown adipose cell fate and thermogenesis through the PRDM16 complex Nature 2013, 504, 163-167
85. Kubicek, S.; OSullivan, R. J.; August, E. M.; Hickey, E. R.; Zhang, Q.; Teodoro, M. L.; Rea, S.; Mechtler, K.; Kowalski, J. A.; Homon, C. A.; Kelly, T. A.; Jenuwein, T. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase Mol. Cell 2007, 25, 473-481
86. Chang, Y.; Zhang, X.; Horton, J. R.; Upadhyay, A. K.; Spannhoff, A.; Liu, J.; Snyder, J. P.; Bedford, M. T.; Cheng, X. Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294 Nat. Struct. Mol. Biol. 2009, 16, 312-317
87. Liu, F.; Chen, X.; Allali-Hassani, A.; Quinn, A. M.; Wasney, G. A.; Dong, A.; Barsyte, D.; Kozieradzki, I.; Senisterra, G.; Chau, I.; Siarheyeva, A.; Kireev, D. B.; Jadhav, A.; Herold, J. M.; Frye, S. V.; Arrowsmith, C. H.; Brown, P. J.; Simeonov, A.; Vedadi, M.; Jin, J. Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a J. Med. Chem. 2009, 52, 7950-7953
88. Liu, F.; Chen, X.; Allali-Hassani, A.; Quinn, A. M.; Wigle, T. J.; Wasney, G. A.; Dong, A.; Senisterra, G.; Chau, I.; Siarheyeva, A.; Norris, J. L.; Kireev, D. B.; Jadhav, A.; Herold, J. M.; Janzen, W. P.; Arrowsmith, C. H.; Frye, S. V.; Brown, P. J.; Simeonov, A.; Vedadi, M.; Jin, J. Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines J. Med. Chem. 2010, 53, 5844-5857
89. Chang, Y.; Ganesh, T.; Horton, J. R.; Spannhoff, A.; Liu, J.; Sun, A.; Zhang, X.; Bedford, M. T.; Shinkai, Y.; Snyder, J. P.; Cheng, X. Adding a lysine mimic in the design of potent inhibitors of histone lysine methyltransferases J. Mol. Biol. 2010, 400, 1-7
90. Liu, F.; Barsyte-Lovejoy, D.; Allali-Hassani, A.; He, Y.; Herold, J. M.; Chen, X.; Yates, C. M.; Frye, S. V.; Brown, P. J.; Huang, J.; Vedadi, M.; Arrowsmith, C. H.; Jin, J. Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines J. Med. Chem. 2011, 54, 6139-6150
91. Vedadi, M.; Barsyte-Lovejoy, D.; Liu, F.; Rival-Gervier, S.; Allali-Hassani, A.; Labrie, V.; Wigle, T. J.; Dimaggio, P. A.; Wasney, G. A.; Siarheyeva, A.; Dong, A.; Tempel, W.; Wang, S. C.; Chen, X.; Chau, I.; Mangano, T. J.; Huang, X. P.; Simpson, C. D.; Pattenden, S. G.; Norris, J. L.; Kireev, D. B.; Tripathy, A.; Edwards, A.; Roth, B. L.; Janzen, W. P.; Garcia, B. A.; Petronis, A.; Ellis, J.; Brown, P. J.; Frye, S. V.; Arrowsmith, C. H.; Jin, J. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells Nat. Chem. Biol. 2011, 7, 566-574
92. Frye, S. V. The art of the chemical probe Nat. Chem. Biol. 2010, 6, 159-161
93. Workman, P.; Collins, I. Probing the probes: fitness factors for small molecule tools Chem. Biol. 2010, 17, 561-577
94. Bunnage, M. E.; Chekler, E. L.; Jones, L. H. Target validation using chemical probes Nat. Chem. Biol. 2013, 9, 195-199
95. Liu, F.; Barsyte-Lovejoy, D.; Li, F.; Xiong, Y.; Korboukh, V.; Huang, X. P.; Allali-Hassani, A.; Janzen, W. P.; Roth, B. L.; Frye, S. V.; Arrowsmith, C. H.; Brown, P. J.; Vedadi, M.; Jin, J. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP J. Med. Chem. 2013, 56, 8931-8942
96. Konze, K. D.; Pattenden, S. G.; Liu, F.; Barsyte-Lovejoy, D.; Li, F.; Simon, J. M.; Davis, I. J.; Vedadi, M.; Jin, J. A chemical tool for in vitro and in vivo precipitation of lysine methyltransferase g9a ChemMedChem. 2014, 9, 549-553
97. Yuan, Y.; Wang, Q.; Paulk, J.; Kubicek, S.; Kemp, M. M.; Adams, D. J.; Shamji, A. F.; Wagner, B. K.; Schreiber, S. L. A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma ACS Chem. Biol. 2012, 7, 1152-1157
98. Sweis, R. F.; Pliushchev, M.; Brown, P. J.; Guo, J.; Li, F.; Maag, D.; Petros, A. M.; Soni, N. B.; Tse, C.; Vedadi, M.; Michaelides, M. R.; Chiang, G. G.; Pappano, W. N. Discovery and development of potent and selective inhibitors of histone methyltransferase G9a ACS Med. Chem. Lett. 2014, 5, 205-209
99. OMeara, M. M.; Simon, J. A. Inner workings and regulatory inputs that control polycomb repressive complex 2 Chromosoma 2012, 121, 221-234
100. Cao, R.; Wang, L.; Wang, H.; Xia, L.; Erdjument-Bromage, H.; Tempst, P.; Jones, R. S.; Zhang, Y. Role of histone H3 lysine 27 methylation in polycomb-group silencing Science 2002, 298, 1039-1043
101. Kuzmichev, A.; Nishioka, K.; Erdjument-Bromage, H.; Tempst, P.; Reinberg, D. Histone methyltransferase activity associated with a human multiprotein complex containing the enhancer of zeste protein Genes Dev. 2002, 16, 2893-2905
102. Margueron, R.; Reinberg, D. The polycomb complex PRC2 and its mark in life Nature 2011, 469, 343-349
103. Czermin, B.; Melfi, R.; McCabe, D.; Seitz, V.; Imhof, A.; Pirrotta, V. Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal polycomb sites Cell 2002, 111, 185-196
104. Muller, J.; Hart, C. M.; Francis, N. J.; Vargas, M. L.; Sengupta, A.; Wild, B.; Miller, E. L.; OConnor, M. B.; Kingston, R. E.; Simon, J. A. Histone methyltransferase activity of a Drosophila polycomb group repressor complex Cell 2002, 111, 197-208
105. Joshi, P.; Carrington, E. A.; Wang, L.; Ketel, C. S.; Miller, E. L.; Jones, R. S.; Simon, J. A. Dominant alleles identify SET domain residues required for histone methyltransferase of polycomb repressive complex 2 J. Biol. Chem. 2008, 283, 27757-27766
106. Verma, S. K.; Tian, X.; LaFrance, L. V.; Duquenne, C.; Suarez, D. P.; Newlander, K. A.; Romeril, S. P.; Burgess, J. L.; Grant, S. W.; Brackley, J. A.; Graves, A. P.; Scherzer, D. A.; Shu, A.; Thompson, C.; Ott, H. M.; Aller, G. S. V.; Machutta, C. A.; Diaz, E.; Jiang, Y.; Johnson, N. W.; Knight, S. D.; Kruger, R. G.; McCabe, M. T.; Dhanak, D.; Tummino, P. J.; Creasy, C. L.; Miller, W. H. Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2 ACS Med. Chem. Lett. 2012, 3, 1091-1096
107. Margueron, R.; Li, G.; Sarma, K.; Blais, A.; Zavadil, J.; Woodcock, C. L.; Dynlacht, B. D.; Reinberg, D. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms Mol. Cell 2008, 32, 503-518
108. Shen, X.; Liu, Y.; Hsu, Y.-J.; Fujiwara, Y.; Kim, J.; Mao, X.; Yuan, G.-C.; Orkin, S. H. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency Mol. Cell 2008, 32, 491-502
109. Zee, B. M.; Levin, R. S.; Xu, B.; LeRoy, G.; Wingreen, N. S.; Garcia, B. A. In vivo residue-specific histone methylation dynamics J. Biol. Chem. 2010, 285, 3341-3350
110. Cao, R.; Zhang, Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex Mol. Cell 2004, 15, 57-67
111. Ketel, C. S.; Andersen, E. F.; Vargas, M. L.; Suh, J.; Strome, S.; Simon, J. A. Subunit contributions to histone methyltransferase activities of fly and worm polycomb group complexes Mol. Cell. Biol. 2005, 25, 6857-6868
112. Pasini, D.; Bracken, A. P.; Jensen, M. R.; Lazzerini Denchi, E.; Helin, K. Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity EMBO J. 2004, 23, 4061-4071
113. Kim, H.; Kang, K.; Kim, J. AEBP2 as a potential targeting protein for polycomb repression complex PRC2 Nucleic Acids Res. 2009, 37, 2940-2950
114. Nekrasov, M.; Klymenko, T.; Fraterman, S.; Papp, B.; Oktaba, K.; Kocher, T.; Cohen, A.; Stunnenberg, H. G.; Wilm, M.; Muller, J. Pcl-PRC2 is needed to generate high levels of H3-K27 trimethylation at polycomb target genes EMBO J. 2007, 26, 4078-4088
115. Walker, E.; Chang, W. Y.; Hunkapiller, J.; Cagney, G.; Garcha, K.; Torchia, J.; Krogan, N. J.; Reiter, J. F.; Stanford, W. L. Polycomb-like 2 associates with PRC2 and regulates transcriptional networks during mouse embryonic stem cell self-renewal and differentiation Cell Stem Cell 2010, 6, 153-166
116. Li, G.; Margueron, R.; Ku, M. C.; Chambon, P.; Bernstein, B. E.; Reinberg, D. Jarid2 and PRC2, partners in regulating gene expression Genes Dev. 2010, 24, 368-380
117. Morin, R. D.; Johnson, N. A.; Severson, T. M.; Mungall, A. J.; An, J.; Goya, R.; Paul, J. E.; Boyle, M.; Woolcock, B. W.; Kuchenbauer, F.; Yap, D.; Humphries, R. K.; Griffith, O. L.; Shah, S.; Zhu, H.; Kimbara, M.; Shashkin, P.; Charlot, J. F.; Tcherpakov, M.; Corbett, R.; Tam, A.; Varhol, R.; Smailus, D.; Moksa, M.; Zhao, Y.; Delaney, A.; Qian, H.; Birol, I.; Schein, J.; Moore, R.; Holt, R.; Horsman, D. E.; Connors, J. M.; Jones, S.; Aparicio, S.; Hirst, M.; Gascoyne, R. D.; Marra, M. A. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin Nat. Genet. 2010, 42, 181-185
118. Morin, R. D.; Mendez-Lago, M.; Mungall, A. J.; Goya, R.; Mungall, K. L.; Corbett, R. D.; Johnson, N. A.; Severson, T. M.; Chiu, R.; Field, M.; Jackman, S.; Krzywinski, M.; Scott, D. W.; Trinh, D. L.; Tamura-Wells, J.; Li, S.; Firme, M. R.; Rogic, S.; Griffith, M.; Chan, S.; Yakovenko, O.; Meyer, I. M.; Zhao, E. Y.; Smailus, D.; Moksa, M.; Chittaranjan, S.; Rimsza, L.; Brooks-Wilson, A.; Spinelli, J. J.; Ben-Neriah, S.; Meissner, B.; Woolcock, B.; Boyle, M.; McDonald, H.; Tam, A.; Zhao, Y. J.; Delaney, A.; Zeng, T.; Tse, K.; Butterfield, Y.; Birol, I.; Holt, R.; Schein, J.; Horsman, D. E.; Moore, R.; Jones, S. J. M.; Connors, J. M.; Hirst, M.; Gascoyne, R. D.; Marra, M. A. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma Nature 2011, 476, 298-303
119. Lohr, J. G.; Stojanov, P.; Lawrence, M. S.; Auclair, D.; Chapuy, B.; Sougnez, C.; Cruz-Gordillo, P.; Knoechel, B.; Asmann, Y. W.; Slager, S. L.; Novak, A. J.; Dogan, A.; Ansell, S. M.; Link, B. K.; Zou, L. H.; Gould, J.; Saksena, G.; Stransky, N.; Rangel-Escareno, C.; Fernandez-Lopez, J. C.; Hidalgo-Miranda, A.; Melendez-Zajgla, J.; Hernandez-Lemus, E.; Celis, A. S. C. Y.; Imaz-Rosshandler, I.; Ojesina, A. I.; Jung, J.; Pedamallu, C. S.; Lander, E. S.; Habermann, T. M.; Cerhan, J. R.; Shipp, M. A.; Getz, G.; Golub, T. R. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 3879-3884
120. Yap, D. B.; Chu, J.; Berg, T.; Schapira, M.; Cheng, S. W.; Moradian, A.; Morin, R. D.; Mungall, A. J.; Meissner, B.; Boyle, M.; Marquez, V. E.; Marra, M. A.; Gascoyne, R. D.; Humphries, R. K.; Arrowsmith, C. H.; Morin, G. B.; Aparicio, S. A. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation Blood 2011, 117, 2451-2459
121. Sneeringer, C. J.; Scott, M. P.; Kuntz, K. W.; Knutson, S. K.; Pollock, R. M.; Richon, V. M.; Copeland, R. A. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 20980-20985
122. McCabe, M. T.; Graves, A. P.; Ganji, G.; Diaz, E.; Halsey, W. S.; Jiang, Y.; Smitheman, K. N.; Ott, H. M.; Pappalardi, M. B.; Allen, K. E.; Chen, S. B.; Della Pietra, A., 3rd; Dul, E.; Hughes, A. M.; Gilbert, S. A.; Thrall, S. H.; Tummino, P. J.; Kruger, R. G.; Brandt, M.; Schwartz, B.; Creasy, C. L. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27) Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 2989-2994
123. Bracken, A. P.; Pasini, D.; Capra, M.; Prosperini, E.; Colli, E.; Helin, K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer EMBO J. 2003, 22, 5323-5335
124. Simon, J. A.; Lange, C. A. Roles of the EZH2 histone methyltransferase in cancer epigenetics Mutat. Res. 2008, 647, 21-29
125. Chi, P.; Allis, C. D.; Wang, G. G. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers Nat. Rev. Cancer 2010, 10, 457-469
126. Kleer, C. G.; Cao, Q.; Varambally, S.; Shen, R.; Ota, I.; Tomlins, S. A.; Ghosh, D.; Sewalt, R. G.; Otte, A. P.; Hayes, D. F.; Sabel, M. S.; Livant, D.; Weiss, S. J.; Rubin, M. A.; Chinnaiyan, A. M. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 11606-11611
127. Varambally, S.; Dhanasekaran, S. M.; Zhou, M.; Barrette, T. R.; Kumar-Sinha, C.; Sanda, M. G.; Ghosh, D.; Pienta, K. J.; Sewalt, R. G.; Otte, A. P.; Rubin, M. A.; Chinnaiyan, A. M. The polycomb group protein EZH2 is involved in progression of prostate cancer Nature 2002, 419, 624-629
128. Velichutina, I.; Shaknovich, R.; Geng, H.; Johnson, N. A.; Gascoyne, R. D.; Melnick, A. M.; Elemento, O. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis Blood 2010, 116, 5247-5255
129. Shih, A. H.; Abdel-Wahab, O.; Patel, J. P.; Levine, R. L. The role of mutations in epigenetic regulators in myeloid malignancies Nat. Rev. Cancer 2012, 12, 599-612
130. Knutson, S. K.; Wigle, T. J.; Warholic, N. M.; Sneeringer, C. J.; Allain, C. J.; Klaus, C. R.; Sacks, J. D.; Raimondi, A.; Majer, C. R.; Song, J.; Scott, M. P.; Jin, L.; Smith, J. J.; Olhava, E. J.; Chesworth, R.; Moyer, M. P.; Richon, V. M.; Copeland, R. A.; Keilhack, H.; Pollock, R. M.; Kuntz, K. W. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells Nat. Chem. Biol. 2012, 8, 890-896
131. Richon, V. M.; Johnston, D.; Sneeringer, C. J.; Jin, L.; Majer, C. R.; Elliston, K.; Jerva, L. F.; Scott, M. P.; Copeland, R. A. Chemogenetic analysis of human protein methyltransferases Chem. Biol. Drug Des 2011, 78, 199-210
132. Yonetani, T.; Theorell, H. Studies on liver alcohol hydrogenase complexes. 3. Multiple inhibition kinetics in the presence of two competitive inhibitors Arch. Biochem. Biophys. 1964, 106, 243-251
133. McCabe, M. T.; Ott, H. M.; Ganji, G.; Korenchuk, S.; Thompson, C.; Van Aller, G. S.; Liu, Y.; Graves, A. P.; III, A. D.; Diaz, E.; Lafrance, L. V.; Mellinger, M.; Duquenne, C.; Tian, X.; Kruger, R. G.; McHugh, C. F.; Brandt, M.; Miller, W. H.; Dhanak, D.; Verma, S. K.; Tummino, P. J.; Creasy, C. L. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations Nature 2012, 492, 108-112
134. Diaz, E.; Machutta, C. A.; Chen, S.; Jiang, Y.; Nixon, C.; Hofmann, G.; Key, D.; Sweitzer, S.; Patel, M.; Wu, Z.; Creasy, C. L.; Kruger, R. G.; LaFrance, L.; Verma, S.; Pappalardi, M. B.; Le, B.; Van Aller, G. S.; McCabe, M. T.; Tummino, P. J.; Pope, A. J.; Thrall, S. H.; Schwartz, B.; Brandt, M. Development and validation of reagents and assays for EZH2 peptide and nucleosome high-throughput screens J. Biomol. Screening 2012, 17, 1279-1292
135. Beguelin, W.; Popovic, R.; Teater, M.; Jiang, Y.; Bunting, K. L.; Rosen, M.; Shen, H.; Yang, S. N.; Wang, L.; Ezponda, T.; Martinez-Garcia, E.; Zhang, H.; Zheng, Y.; Verma, S. K.; McCabe, M. T.; Ott, H. M.; Van Aller, G. S.; Kruger, R. G.; Liu, Y.; McHugh, C. F.; Scott, D. W.; Chung, Y. R.; Kelleher, N.; Shaknovich, R.; Creasy, C. L.; Gascoyne, R. D.; Wong, K. K.; Cerchietti, L.; Levine, R. L.; Abdel-Wahab, O.; Licht, J. D.; Elemento, O.; Melnick, A. M. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation Cancer Cell 2013, 23, 677-692
136. A study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK2816126 in subjects with relapsed/refractory diffuse large B cell and transformed follicular lymphoma; http://clinicaltrials.gov/ct2/show/NCT02082977?term=NCT02082977&=1.
137. Qi, W.; Chan, H.; Teng, L.; Li, L.; Chuai, S.; Zhang, R.; Zeng, J.; Li, M.; Fan, H.; Lin, Y.; Gu, J.; Ardayfio, O.; Zhang, J.-H.; Yan, X.; Fang, J.; Mi, Y.; Zhang, M.; Zhou, T.; Feng, G.; Chen, Z.; Li, G.; Yang, T.; Zhao, K.; Liu, X.; Yu, Z.; Lu, C. X.; Atadja, P.; Li, E. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 21360-21365
138. Konze, K. D.; Ma, A.; Li, F.; Barsyte-Lovejoy, D.; Parton, T.; MacNevin, C. J.; Liu, F.; Gao, C.; Huang, X. P.; Kuznetsova, E.; Rougie, M.; Jiang, A.; Pattenden, S. G.; Norris, J. L.; James, L. I.; Roth, B. L.; Brown, P. J.; Frye, S. V.; Arrowsmith, C. H.; Hahn, K. M.; Wang, G. G.; Vedadi, M.; Jin, J. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1 ACS Chem. Biol. 2013, 8, 1324-1334
139. Knutson, S. K.; Warholic, N. M.; Wigle, T. J.; Klaus, C. R.; Allain, C. J.; Raimondi, A.; Porter Scott, M.; Chesworth, R.; Moyer, M. P.; Copeland, R. A.; Richon, V. M.; Pollock, R. M.; Kuntz, K. W.; Keilhack, H. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 7922-7927
140. Wilson, B. G.; Roberts, C. W. SWI/SNF nucleosome remodellers and cancer Nat. Rev. Cancer 2011, 11, 481-492
141. Wilson, B. G.; Wang, X.; Shen, X.; McKenna, E. S.; Lemieux, M. E.; Cho, Y. J.; Koellhoffer, E. C.; Pomeroy, S. L.; Orkin, S. H.; Roberts, C. W. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation Cancer Cell 2010, 18, 316-328
142. Study of E7438 (EZH2 histone methyl transferase [HMT] inhibitor) as a single agent in subjects with advanced solid tumors or with B cell lymphomas; http://clinicaltrials.gov/ct2/show/NCT01897571?term=NCT01897571&=1.
143. Garapaty-Rao, S.; Nasveschuk, C.; Gagnon, A.; Chan, E. Y.; Sandy, P.; Busby, J.; Balasubramanian, S.; Campbell, R.; Zhao, F.; Bergeron, L.; Audia, J. E.; Albrecht, B. K.; Harmange, J. C.; Cummings, R.; Trojer, P. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth Chem. Biol. 2013, 20, 1329-1339
144. Nasveschuk, C. G.; Gagnon, A.; Garapaty-Rao, S.; Balasubramanian, S.; Campbell, R.; Lee, C.; Zhao, F.; Bergeron, L.; Cummings, R.; Trojer, P.; Audia, J. E.; Albrecht, B. K.; Harmange, J. C. Discovery and optimization of tetramethylpiperidinyl benzamides as inhibitors of EZH2 ACS Med. Chem. Lett. 2014, 5, 378-383
145. Ruthenburg, A. J.; Allis, C. D.; Wysocka, J. Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark Mol. Cell 2007, 25, 15-30
146. Brown, M. A.; Sims, R. J., III; Gottlieb, P. D.; Tucker, P. W. Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex Mol. Cancer 2006, 5, 26
147. Dillon, S. C.; Zhang, X.; Trievel, R. C.; Cheng, X. The SET-domain protein superfamily: protein lysine methyltransferases Genome Biol. 2005, 6, 227
148. Avdic, V.; Zhang, P.; Lanouette, S.; Groulx, A.; Tremblay, V.; Brunzelle, J.; Couture, J. F. Structural and biochemical insights into MLL1 core complex assembly Structure 2011, 19, 101-108
149. Krivtsov, A. V.; Armstrong, S. A. MLL translocations, histone modifications and leukaemia stem-cell development Nat. Rev. Cancer 2007, 7, 823-833
150. Albert, M.; Helin, K. Histone methyltransferases in cancer Semin. Cell Dev. Biol. 2010, 21, 209-220
151. Kohlmann, A.; Schoch, C.; Dugas, M.; Schnittger, S.; Hiddemann, W.; Kern, W.; Haferlach, T. New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes Leukemia 2005, 19, 953-964
152. Hess, J. L. MLL: a histone methyltransferase disrupted in leukemia Trends Mol. Med. 2004, 10, 500-507
153. Yu, B. D.; Hess, J. L.; Horning, S. E.; Brown, G. A.; Korsmeyer, S. J. Altered Hox expression and segmental identity in Mll-mutant mice Nature 1995, 378, 505-508
154. Karatas, H.; Townsend, E. C.; Cao, F.; Chen, Y.; Bernard, D.; Liu, L.; Lei, M.; Dou, Y.; Wang, S. High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction J. Am. Chem. Soc. 2013, 135, 669-682
155. Senisterra, G.; Wu, H.; Allali-Hassani, A.; Wasney, G. A.; Barsyte-Lovejoy, D.; Dombrovski, L.; Dong, A.; Nguyen, K. T.; Smil, D.; Bolshan, Y.; Hajian, T.; He, H.; Seitova, A.; Chau, I.; Li, F.; Poda, G.; Couture, J. F.; Brown, P. J.; Al-Awar, R.; Schapira, M.; Arrowsmith, C. H.; Vedadi, M. Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5 Biochem. J. 2013, 449, 151-159
156. Pradhan, S.; Chin, H. G.; Esteve, P. O.; Jacobsen, S. E. SET7/9 mediated methylation of non-histone proteins in mammalian cells Epigenetics 2009, 4, 383-387
157. Siebel, A. L.; Fernandez, A. Z.; El-Osta, A. Glycemic memory associated epigenetic changes Biochem. Pharmacol. 2010, 80, 1853-1859
158. Barsyte-Lovejoy, D.; Li, F.; Oudhoff, M. J.; Tatlock, J. H.; Dong, A.; Zeng, H.; Wu, H.; Freeman, S. A.; Schapira, M.; Senisterra, G. A.; Kuznetsova, E.; Marcellus, R.; Allali-Hassani, A.; Kennedy, S.; Lambert, J. P.; Couzens, A. L.; Aman, A.; Gingras, A. C.; Al-Awar, R.; Fish, P. V.; Gerstenberger, B. S.; Roberts, L.; Benn, C. L.; Grimley, R. L.; Braam, M. J.; Rossi, F. M.; Sudol, M.; Brown, P. J.; Bunnage, M. E.; Owen, D. R.; Zaph, C.; Vedadi, M.; Arrowsmith, C. H. (R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells Proc. Natl. Acad. Sci. U.S.A. 2014, 111, 12853-12858
159. Gottlieb, P. D.; Pierce, S. A.; Sims, R. J.; Yamagishi, H.; Weihe, E. K.; Harriss, J. V.; Maika, S. D.; Kuziel, W. A.; King, H. L.; Olson, E. N.; Nakagawa, O.; Srivastava, D. Bop encodes a muscle-restricted protein containing MYND and SET domains and is essential for cardiac differentiation and morphogenesis Nat. Genet. 2002, 31, 25-32
160. Hamamoto, R.; Furukawa, Y.; Morita, M.; Iimura, Y.; Silva, F. P.; Li, M.; Yagyu, R.; Nakamura, Y. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells Nat. Cell Biol. 2004, 6, 731-740
161. Hamamoto, R.; Silva, F. P.; Tsuge, M.; Nishidate, T.; Katagiri, T.; Nakamura, Y.; Furukawa, Y. Enhanced SMYD3 expression is essential for the growth of breast cancer cells Cancer Sci. 2006, 97, 113-118
162. Mazur, P. K.; Reynoird, N.; Khatri, P.; Jansen, P. W. T. C.; Wilkinson, A. W.; Liu, S. C.; Barbash, O.; Van Aller, G. S.; Huddleston, M.; Dhanak, D.; Tummino, P. J.; Kruger, R. G.; Garcia, B. A.; Butte, A. J.; Vermeulen, M.; Sage, J.; Gozani, O. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer Nature 2014, 510, 283-287
163. Abu-Farha, M.; Lambert, J. P.; Al-Madhoun, A. S.; Elisma, F.; Skerjanc, I. S.; Figeys, D. The tale of two domains: proteomics and genomics analysis of SMYD2, a new histone methyltransferase Mol. Cell. Proteomics 2008, 7, 560-572
164. Huang, J.; Perez-Burgos, L.; Placek, B. J.; Sengupta, R.; Richter, M.; Dorsey, J. A.; Kubicek, S.; Opravil, S.; Jenuwein, T.; Berger, S. L. Repression of p53 activity by Smyd2-mediated methylation Nature 2006, 444, 629-632
165. Saddic, L. A.; West, L. E.; Aslanian, A.; Yates, J. R., III; Rubin, S. M.; Gozani, O.; Sage, J. Methylation of the retinoblastoma tumor suppressor by SMYD2 J. Biol. Chem. 2010, 285, 37733-37740
166. Sakamoto, L. H.; Andrade, R. V.; Felipe, M. S.; Motoyama, A. B.; Pittella Silva, F. SMYD2 is highly expressed in pediatric acute lymphoblastic leukemia and constitutes a bad prognostic factor Leuk. Res. 2014, 38, 496-502
167. Komatsu, S.; Imoto, I.; Tsuda, H.; Kozaki, K. I.; Muramatsu, T.; Shimada, Y.; Aiko, S.; Yoshizumi, Y.; Ichikawa, D.; Otsuji, E.; Inazawa, J. Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma Carcinogenesis 2009, 30, 1139-1146
168. Ferguson, A. D.; Larsen, N. A.; Howard, T.; Pollard, H.; Green, I.; Grande, C.; Cheung, T.; Garcia-Arenas, R.; Cowen, S.; Wu, J.; Godin, R.; Chen, H.; Keen, N. Structural basis of substrate methylation and inhibition of SMYD2 Structure 2011, 19, 1262-1273
169. LLY-507: A chemical probe for SMYD2 protein lysine methyltransferase; http://www.thesgc.org/chemical-probes/LLY-507.
170. de Almeida, S. F.; Grosso, A. R.; Koch, F.; Fenouil, R.; Carvalho, S.; Andrade, J.; Levezinho, H.; Gut, M.; Eick, D.; Gut, I.; Andrau, J. C.; Ferrier, P.; Carmo-Fonseca, M. Splicing enhances recruitment of methyltransferase HYPB/Setd2 and methylation of histone H3 Lys36 Nat. Struct. Mol. Biol. 2011, 18, 977-983
171. Newbold, R. F.; Mokbel, K. Evidence for a tumour suppressor function of SETD2 in human breast cancer: a new hypothesis Anticancer Res. 2010, 30, 3309-3311
172. Hu, M.; Sun, X. J.; Zhang, Y. L.; Kuang, Y.; Hu, C. Q.; Wu, W. L.; Shen, S. H.; Du, T. T.; Li, H.; He, F.; Xiao, H. S.; Wang, Z. G.; Liu, T. X.; Lu, H.; Huang, Q. H.; Chen, S. J.; Chen, Z. Histone H3 lysine 36 methyltransferase Hypb/Setd2 is required for embryonic vascular remodeling Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 2956-2961
173. Zhu, X.; He, F.; Zeng, H.; Ling, S.; Chen, A.; Wang, Y.; Yan, X.; Wei, W.; Pang, Y.; Cheng, H.; Hua, C.; Zhang, Y.; Yang, X.; Lu, X.; Cao, L.; Hao, L.; Dong, L.; Zou, W.; Wu, J.; Li, X.; Zheng, S.; Yan, J.; Zhou, J.; Zhang, L.; Mi, S.; Wang, X.; Zhang, L.; Zou, Y.; Chen, Y.; Geng, Z.; Wang, J.; Zhou, J.; Liu, X.; Wang, J.; Yuan, W.; Huang, G.; Cheng, T.; Wang, Q. F. Identification of functional cooperative mutations of SETD2 in human acute leukemia Nat. Genet. 2014, 46, 287-293
174. Fontebasso, A. M.; Schwartzentruber, J.; Khuong-Quang, D. A.; Liu, X. Y.; Sturm, D.; Korshunov, A.; Jones, D. T.; Witt, H.; Kool, M.; Albrecht, S.; Fleming, A.; Hadjadj, D.; Busche, S.; Lepage, P.; Montpetit, A.; Staffa, A.; Gerges, N.; Zakrzewska, M.; Zakrzewski, K.; Liberski, P. P.; Hauser, P.; Garami, M.; Klekner, A.; Bognar, L.; Zadeh, G.; Faury, D.; Pfister, S. M.; Jabado, N.; Majewski, J. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas Acta Neuropathol. 2013, 125, 659-669
175. Zheng, W.; Ibáñez, G.; Wu, H.; Blum, G.; Zeng, H.; Dong, A.; Li, F.; Hajian, T.; Allali-Hassani, A.; Amaya, M. F.; Siarheyeva, A.; Yu, W.; Brown, P. J.; Schapira, M.; Vedadi, M.; Min, J.; Luo, M. Sinefungin derivatives as inhibitors and structure probes of protein lysine methyltransferase SETD2 J. Am. Chem. Soc. 2012, 134, 18004-18014
176. Beck, D. B.; Oda, H.; Shen, S. S.; Reinberg, D. PR-Set7 and H4K20me1: at the crossroads of genome integrity, cell cycle, chromosome condensation, and transcription Genes Dev. 2012, 26, 325-337
177. Nishioka, K.; Rice, J. C.; Sarma, K.; Erdjument-Bromage, H.; Werner, J.; Wang, Y.; Chuikov, S.; Valenzuela, P.; Tempst, P.; Steward, R.; Lis, J. T.; Allis, C. D.; Reinberg, D. PR-Set7 is a nucleosome-specific methyltransferase that modifies lysine 20 of histone H4 and is associated with silent chromatin Mol. Cell 2002, 9, 1201-1213
178. Fang, J.; Feng, Q.; Ketel, C. S.; Wang, H.; Cao, R.; Xia, L.; Erdjument-Bromage, H.; Tempst, P.; Simon, J. A.; Zhang, Y. Purification and functional characterization of SET8, a nucleosomal histone H4-lysine 20-specific methyltransferase Curr. Biol. 2002, 12, 1086-1099
179. Takawa, M.; Cho, H. S.; Hayami, S.; Toyokawa, G.; Kogure, M.; Yamane, Y.; Iwai, Y.; Maejima, K.; Ueda, K.; Masuda, A.; Dohmae, N.; Field, H. I.; Tsunoda, T.; Kobayashi, T.; Akasu, T.; Sugiyama, M.; Ohnuma, S.; Atomi, Y.; Ponder, B. A. J.; Nakamura, Y.; Hamamoto, R. Histone lysine methyltransferase SETD8 promotes carcinogenesis by deregulating PCNA expression Cancer Res. 2012, 72, 3217-3227
180. Williams, D. E.; Dalisay, D. S.; Li, F.; Amphlett, J.; Maneerat, W.; Chavez, M. A. G.; Wang, Y. A.; Matainaho, T.; Yu, W.; Brown, P. J.; Arrowsmith, C. H.; Vedadi, M.; Andersen, R. J. Nahuoic acid A produced by a Streptomyces sp. isolated from a marine sediment is a selective SAM-competitive inhibitor of the histone methyltransferase SETD8 Org. Lett. 2013, 15, 414-417
181. Ma, A.; Yu, W.; Li, F.; Bleich, R. M.; Herold, J. M.; Butler, K. V.; Norris, J. L.; Korboukh, V.; Tripathy, A.; Janzen, W. P.; Arrowsmith, C. H.; Frye, S. V.; Vedadi, M.; Brown, P. J.; Jin, J. Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8 J. Med. Chem. 2014, 57, 6822-6833
182. Ma, A.; Yu, W.; Xiong, Y.; Butler, K. V.; Brown, P. J.; Jin, J. Structure-activity relationship studies of SETD8 inhibitors Med. Chem. Comm 2014, 5, 1892-1898
183. Blum, G.; Ibanez, G.; Rao, X.; Shum, D.; Radu, C.; Djaballah, H.; Rice, J. C.; Luo, M. Small-molecule inhibitors of SETD8 with cellular activity ACS Chem. Biol. 2014, 9, 2471-2478
184. Feng, Q.; Wang, H.; Ng, H. H.; Erdjument-Bromage, H.; Tempst, P.; Struhl, K.; Zhang, Y. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain Curr. Biol. 2002, 12, 1052-1058
185. Min, J.; Feng, Q.; Li, Z.; Zhang, Y.; Xu, R. M. Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase Cell 2003, 112, 711-723
186. Schubert, H. L.; Blumenthal, R. M.; Cheng, X. D. Many paths to methyltransfer: a chronicle of convergence Trends Biochem. Sci. 2003, 28, 329-335
187. Frederiks, F.; Tzouros, M.; Oudgenoeg, G.; van Welsem, T.; Fornerod, M.; Krijgsveld, J.; van Leeuwen, F. Nonprocessive methylation by Dot1 leads to functional redundancy of histone H3K79 methylation states Nat. Struct. Mol. Biol. 2008, 15, 550-557
188. Nguyen, A. T.; Zhang, Y. The diverse functions of Dot1 and H3K79 methylation Genes Dev. 2011, 25, 1345-1358
189. Nguyen, A. T.; He, J.; Taranova, O.; Zhang, Y. Essential role of DOT1L in maintaining normal adult hematopoiesis Cell Res. 2011, 21, 1370-1373
190. Nguyen, A. T.; Xiao, B.; Neppl, R. L.; Kallin, E. M.; Li, J. A.; Chen, T. P.; Wang, D. Z.; Xiao, X. A.; Zhang, Y. DOT1L regulates dystrophin expression and is critical for cardiac function Genes Dev. 2011, 25, 263-274
191. Nguyen, A. T.; Taranova, O.; He, J.; Zhang, Y. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis Blood 2011, 117, 6912-6922
192. Bitoun, E.; Oliver, P. L.; Davies, K. E. The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling Hum. Mol. Genet. 2007, 16, 92-106
193. Mueller, D.; Bach, C.; Zeisig, D.; Garcia-Cuellar, M. P.; Monroe, S.; Sreekumar, A.; Zhou, R.; Nesvizhskii, A.; Chinnaiyan, A.; Hess, J. L.; Slany, R. K. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification Blood 2007, 110, 4445-4454
194. Yokoyama, A.; Lin, M.; Naresh, A.; Kitabayashi, I.; Cleary, M. L. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription Cancer Cell 2010, 17, 198-212
195. Biswas, D.; Milne, T. A.; Basrur, V.; Kim, J.; Elenitoba-Johnson, K. S. J.; Allis, C. D.; Roeder, R. G. Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 15751-15756
196. Anglin, J. L.; Song, Y. A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L J. Med. Chem. 2013, 56, 8972-8983
197. Daigle, S. R.; Olhava, E. J.; Therkelsen, C. A.; Majer, C. R.; Sneeringer, C. J.; Song, J.; Johnston, L. D.; Scott, M. P.; Smith, J. J.; Xiao, Y.; Jin, L.; Kuntz, K. W.; Chesworth, R.; Moyer, M. P.; Bernt, K. M.; Tseng, J. C.; Kung, A. L.; Armstrong, S. A.; Copeland, R. A.; Richon, V. M.; Pollock, R. M. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor Cancer Cell 2011, 20, 53-65
198. Basavapathruni, A.; Jin, L.; Daigle, S. R.; Majer, C. R.; Therkelsen, C. A.; Wigle, T. J.; Kuntz, K. W.; Chesworth, R.; Pollock, R. M.; Scott, M. P.; Moyer, M. P.; Richon, V. M.; Copeland, R. A.; Olhava, E. J. Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L Chem. Biol. Drug Des. 2012, 80, 971-980
199. Yu, W.; Chory, E. J.; Wernimont, A. K.; Tempel, W.; Scopton, A.; Federation, A.; Marineau, J. J.; Qi, J.; Barsyte-Lovejoy, D.; Yi, J.; Marcellus, R.; Iacob, R. E.; Engen, J. R.; Griffin, C.; Aman, A.; Wienholds, E.; Li, F.; Pineda, J.; Estiu, G.; Shatseva, T.; Hajian, T.; Al-awar, R.; Dick, J. E.; Vedadi, M.; Brown, P. J.; Arrowsmith, C. H.; Bradner, J. E.; Schapira, M. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors Nat. Commun. 2012, 3, 1288
200. Bernt, K. M.; Zhu, N.; Sinha, A. U.; Vempati, S.; Faber, J.; Krivtsov, A. V.; Feng, Z. H.; Punt, N.; Daigle, A.; Bullinger, L.; Pollock, R. M.; Richon, V. M.; Kung, A. L.; Armstrong, S. A. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L Cancer Cell 2011, 20, 66-78
201. Yao, Y.; Chen, P.; Diao, J.; Cheng, G.; Deng, L.; Anglin, J. L.; Prasad, B. V. V; Song, Y. Selective inhibitors of histone methyltransferase DOT1L: design, synthesis and crystallographic studies J. Am. Chem. Soc. 2011, 133, 16746-16749
202. Anglin, J. L.; Deng, L.; Yao, Y.; Cai, G.; Liu, Z.; Jiang, H.; Cheng, G.; Chen, P.; Dong, S.; Song, Y. Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L J. Med. Chem. 2012, 55, 8066-8074
203. Daigle, S. R.; Olhava, E. J.; Therkelsen, C. A.; Basavapathruni, A.; Jin, L.; Boriack-Sjodin, P. A.; Allain, C. J.; Klaus, C. R.; Raimondi, A.; Scott, M. P.; Waters, N. J.; Chesworth, R.; Moyer, M. P.; Copeland, R. A.; Richon, V. M.; Pollock, R. M. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia Blood 2013, 122, 1017-1025
204. Chen, L.; Deshpande, A. J.; Banka, D.; Bernt, K. M.; Dias, S.; Buske, C.; Olhava, E. J.; Daigle, S. R.; Richon, V. M.; Pollock, R. M.; Armstrong, S. A. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l Leukemia 2013, 27, 813-822
205. Deshpande, A. J.; Chen, L.; Fazio, M.; Sinha, A. U.; Bernt, K. M.; Banka, D.; Dias, S.; Chang, J.; Olhava, E. J.; Daigle, S. R.; Richon, V. M.; Pollock, R. M.; Armstrong, S. A. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l Blood 2013, 121, 2533-2541
206. Dose escalation study of EPZ-5676 in pediatric patients with leukemias bearing a rearrangement of the MLL gene; http://clinicaltrials.gov/ct2/show/NCT02141828?term=NCT02141828&=1.
207. A first-in-human phase 1 and expanded cohort study of EPZ-5676 in advanced hematologic malignancies, including acute leukemia with rearrangement of the MLL gene; http://clinicaltrials.gov/ct2/show/NCT01684150?term=NCT01684150&=1.
208. Bedford, M. T.; Clarke, S. G. Protein arginine methylation in mammals: who, what, and why Mol. Cell 2009, 33, 1-13
209. Najbauer, J.; Johnson, B. A.; Young, A. L.; Aswad, D. W. Peptides with sequences similar to glycine, arginine-rich motifs in proteins interacting with RNA are efficiently recognized by methyltransferase(s) modifying arginine in numerous proteins J. Biol. Chem. 1993, 268, 10501-10509
210. G-dimethylarginine in nuclear protein fractions Biochem. Biophys. Res. Commun. 1977, 74, 969-976
211. p°, and the cold denatured state J. Am. Chem. Soc. 2006, 128, 12735-12742
212. Bedford, M. T.; Richard, S. Arginine methylation an emerging regulator of protein function Mol. Cell 2005, 18, 263-272
213. Yang, Y.; Bedford, M. T. Protein arginine methyltransferases and cancer Nat. Rev. Cancer 2013, 13, 37-50
214. Zhang, X.; Zhou, L.; Cheng, X. Crystal structure of the conserved core of protein arginine methyltransferase PRMT3 EMBO J. 2000, 19, 3509-3519
215. Zhang, X.; Cheng, X. Structure of the predominant protein arginine methyltransferase PRMT1 and analysis of its binding to substrate peptides Structure 2003, 11, 509-520
216. Lee, J.; Bedford, M. T. PABP1 identified as an arginine methyltransferase substrate using high-density protein arrays EMBO Rep. 2002, 3, 268-273
217. Cheng, D.; Cote, J.; Shaaban, S.; Bedford, M. T. The arginine methyltransferase CARM1 regulates the coupling of transcription and mRNA processing Mol. Cell 2007, 25, 71-83
218. Branscombe, T. L.; Frankel, A.; Lee, J. H.; Cook, J. R.; Yang, Z.; Pestka, S.; Clarke, S. PRMT5 (Janus kinase-binding protein 1) catalyzes the formation of symmetric dimethylarginine residues in proteins J. Biol. Chem. 2001, 276, 32971-32976
219. Jansson, M.; Durant, S. T.; Cho, E. C.; Sheahan, S.; Edelmann, M.; Kessler, B.; La Thangue, N. B. Arginine methylation regulates the p53 response Nat. Cell Biol. 2008, 10, 1431-1439
220. Lin, W. J.; Gary, J. D.; Yang, M. C.; Clarke, S.; Herschman, H. R. The mammalian immediate-early TIS21 protein and the leukemia-associated BTG1 protein interact with a protein-arginine N-methyltransferase J. Biol. Chem. 1996, 271, 15034-15044
221. Tang, J.; Frankel, A.; Cook, R. J.; Kim, S.; Paik, W. K.; Williams, K. R.; Clarke, S.; Herschman, H. R. PRMT1 is the predominant type I protein arginine methyltransferase in mammalian cells J. Biol. Chem. 2000, 275, 7723-7730
222. Wang, H.; Huang, Z. Q.; Xia, L.; Feng, Q.; Erdjument-Bromage, H.; Strahl, B. D.; Briggs, S. D.; Allis, C. D.; Wong, J.; Tempst, P.; Zhang, Y. Methylation of histone H4 at arginine 3 facilitating transcriptional activation by nuclear hormone receptor Science 2001, 293, 853-857
223. Strahl, B. D.; Briggs, S. D.; Brame, C. J.; Caldwell, J. A.; Koh, S. S.; Ma, H.; Cook, R. G.; Shabanowitz, J.; Hunt, D. F.; Stallcup, M. R.; Allis, C. D. Methylation of histone H4 at arginine 3 occurs in vivo and is mediated by the nuclear receptor coactivator PRMT1 Curr. Biol. 2001, 11, 996-1000
224. Goulet, I.; Gauvin, G.; Boisvenue, S.; Cote, J. Alternative splicing yields protein arginine methyltransferase 1 isoforms with distinct activity, substrate specificity, and subcellular localization J. Biol. Chem. 2007, 282, 33009-33021
225. Baldwin, R. M.; Morettin, A.; Paris, G.; Goulet, I.; Cote, J. Alternatively spliced protein arginine methyltransferase 1 isoform PRMT1v2 promotes the survival and invasiveness of breast cancer cells Cell Cycle 2012, 11, 4597-4612
226. Seligson, D. B.; Horvath, S.; Shi, T.; Yu, H.; Tze, S.; Grunstein, M.; Kurdistani, S. K. Global histone modification patterns predict risk of prostate cancer recurrence Nature 2005, 435, 1262-1266
227. Teyssier, C.; Le Romancer, M.; Sentis, S.; Jalaguier, S.; Corbo, L.; Cavailles, V. Protein arginine methylation in estrogen signaling and estrogen-related cancers Trends Endocrinol. Metab. 2010, 21, 181-189
228. Le Romancer, M.; Treilleux, I.; Bouchekioua-Bouzaghou, K.; Sentis, S.; Corbo, L. Methylation, a key step for nongenomic estrogen signaling in breast tumors Steroids 2010, 75, 560-564
229. Cheung, N.; Chan, L. C.; Thompson, A.; Cleary, M. L.; So, C. W. Protein arginine-methyltransferase-dependent oncogenesis Nat. Cell Biol. 2007, 9, 1208-1215
230. Shia, W. J.; Okumura, A. J.; Yan, M.; Sarkeshik, A.; Lo, M. C.; Matsuura, S.; Komeno, Y.; Zhao, X.; Nimer, S. D.; Yates, J. R., III; Zhang, D. E. PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential Blood 2012, 119, 4953-4962
231. Yoshimatsu, M.; Toyokawa, G.; Hayami, S.; Unoki, M.; Tsunoda, T.; Field, H. I.; Kelly, J. D.; Neal, D. E.; Maehara, Y.; Ponder, B. A.; Nakamura, Y.; Hamamoto, R. Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers Int. J. Cancer 2011, 128, 562-573
232. Mathioudaki, K.; Papadokostopoulou, A.; Scorilas, A.; Xynopoulos, D.; Agnanti, N.; Talieri, M. The PRMT1 gene expression pattern in colon cancer Br. J. Cancer 2008, 99, 2094-2099
233. Mathioudaki, K.; Scorilas, A.; Ardavanis, A.; Lymberi, P.; Tsiambas, E.; Devetzi, M.; Apostolaki, A.; Talieri, M. Clinical evaluation of PRMT1 gene expression in breast cancer Tumour Biol. 2011, 32, 575-582
234. Papadokostopoulou, A.; Mathioudaki, K.; Scorilas, A.; Xynopoulos, D.; Ardavanis, A.; Kouroumalis, E.; Talieri, M. Colon cancer and protein arginine methyltransferase 1 gene expression Anticancer Res. 2009, 29, 1361-1366
235. Wang, S.; Tan, X.; Yang, B.; Yin, B.; Yuan, J.; Qiang, B.; Peng, X. The role of protein arginine-methyltransferase 1 in gliomagenesis BMB Rep. 2012, 45, 470-475
236. Mitchell, T. R.; Glenfield, K.; Jeyanthan, K.; Zhu, X. D. Arginine methylation regulates telomere length and stability Mol. Cell. Biol. 2009, 29, 4918-4934
237. Sakamaki, J.; Daitoku, H.; Ueno, K.; Hagiwara, A.; Yamagata, K.; Fukamizu, A. Arginine methylation of BCL-2 antagonist of cell death (BAD) counteracts its phosphorylation and inactivation by Akt Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 6085-6090
238. Yamagata, K.; Daitoku, H.; Takahashi, Y.; Namiki, K.; Hisatake, K.; Kako, K.; Mukai, H.; Kasuya, Y.; Fukamizu, A. Arginine methylation of FOXO transcription factors inhibits their phosphorylation by Akt Mol. Cell 2008, 32, 221-231
239. Yu, Z.; Vogel, G.; Coulombe, Y.; Dubeau, D.; Spehalski, E.; Hebert, J.; Ferguson, D. O.; Masson, J. Y.; Richard, S. The MRE11 GAR motif regulates DNA double-strand break processing and ATR activation Cell Res. 2012, 22, 305-320
240. Boisvert, F. M.; Rhie, A.; Richard, S.; Doherty, A. J. The GAR motif of 53BP1 is arginine methylated by PRMT1 and is necessary for 53BP1 DNA binding activity Cell Cycle 2005, 4, 1834-1841
241. Butler, J. S.; Zurita-Lopez, C. I.; Clarke, S. G.; Bedford, M. T.; Dent, S. Y. Protein-arginine methyltransferase 1 (PRMT1) methylates Ash2L, a shared component of mammalian histone H3K4 methyltransferase complexes J. Biol. Chem. 2011, 286, 12234-12244
242. Guendel, I.; Carpio, L.; Pedati, C.; Schwartz, A.; Teal, C.; Kashanchi, F.; Kehn-Hall, K. Methylation of the tumor suppressor protein, BRCA1, influences its transcriptional cofactor function PLoS One 2010, 5, e11379
243. Cheng, D.; Yadav, N.; King, R. W.; Swanson, M. S.; Weinstein, E. J.; Bedford, M. T. Small molecule regulators of protein arginine methyltransferases J. Biol. Chem. 2004, 279, 23892-23899
244. Ragno, R.; Simeoni, S.; Castellano, S.; Vicidomini, C.; Mai, A.; Caroli, A.; Tramontano, A.; Bonaccini, C.; Trojer, P.; Bauer, I.; Brosch, G.; Sbardella, G. Small molecule inhibitors of histone arginine methyltransferases: homology modeling, molecular docking, binding mode analysis, and biological evaluations J. Med. Chem. 2007, 50, 1241-1253
245. Sams-Dodd, F. Target-based drug discovery: is something wrong? Drug Discovery Today 2005, 10, 139-147
246. Spannhoff, A.; Heinke, R.; Bauer, I.; Trojer, P.; Metzger, E.; Gust, R.; Schule, R.; Brosch, G.; Sippl, W.; Jung, M. Target-based approach to inhibitors of histone arginine methyltransferases J. Med. Chem. 2007, 50, 2319-2325
247. Spannhoff, A.; Machmur, R.; Heinke, R.; Trojer, P.; Bauer, I.; Brosch, G.; Schule, R.; Hanefeld, W.; Sippl, W.; Jung, M. A novel arginine methyltransferase inhibitor with cellular activity Bioorg. Med. Chem. Lett. 2007, 17, 4150-4153
248. Heinke, R.; Spannhoff, A.; Meier, R.; Trojer, P.; Bauer, I.; Jung, M.; Sippl, W. Virtual screening and biological characterization of novel histone arginine methyltransferase PRMT1 inhibitors ChemMedChem 2009, 4, 69-77
249. Bonham, K.; Hemmers, S.; Lim, Y. H.; Hill, D. M.; Finn, M. G.; Mowen, K. A. Effects of a novel arginine methyltransferase inhibitor on T-helper cell cytokine production FEBS J. 2010, 277, 2096-2108
250. Feng, Y.; Li, M.; Wang, B.; Zheng, Y. G. Discovery and mechanistic study of a class of protein arginine methylation inhibitors J. Med. Chem. 2010, 53, 6028-6039
251. Dowden, J.; Pike, R. A.; Parry, R. V.; Hong, W.; Muhsen, U. A.; Ward, S. G. Small molecule inhibitors that discriminate between protein arginine N-methyltransferases PRMT1 and CARM1 Org. Biomol. Chem. 2011, 9, 7814-7821
252. Dillon, M. B. C.; Bachovchin, D. A.; Brown, S. J.; Finn, M. G.; Rosen, H.; Cravatt, B. F.; Mowen, K. A. Novel inhibitors for PRMT1 discovered by high-throughput screening using activity-based fluorescence polarization ACS Chem. Biol. 2012, 7, 1198-1204
253. Wang, J.; Chen, L.; Sinha, S. H.; Liang, Z.; Chai, H.; Muniyan, S.; Chou, Y. W.; Yang, C.; Yan, L.; Feng, Y.; Kathy, L. K.; Lin, M. F.; Jiang, H.; George Zheng, Y.; Luo, C. Pharmacophore-based virtual screening and biological evaluation of small molecule inhibitors for protein arginine methylation J. Med. Chem. 2012, 55, 7978-7987
254. Yan, L.; Yan, C.; Qian, K.; Su, H.; Kofsky-Wofford, S. A.; Lee, W. C.; Zhao, X.; Ho, M. C.; Ivanov, I.; Zheng, Y. G. Diamidine compounds for selective inhibition of protein arginine methyltransferase 1 J. Med. Chem. 2014, 57, 2611-2622
255. Tang, J.; Gary, J. D.; Clarke, S.; Herschman, H. R. PRMT 3, a type I protein arginine N-methyltransferase that differs from PRMT1 in its oligomerization, subcellular localization, substrate specificity, and regulation J. Biol. Chem. 1998, 273, 16935-16945
256. Bachand, F.; Silver, P. A. PRMT3 is a ribosomal protein methyltransferase that affects the cellular levels of ribosomal subunits EMBO J. 2004, 23, 2641-2650
257. Swiercz, R.; Person, M. D.; Bedford, M. T. Ribosomal protein S2 is a substrate for mammalian PRMT3 (protein arginine methyltransferase 3) Biochem. J. 2005, 386, 85-91
258. Di Lorenzo, A.; Bedford, M. T. Histone arginine methylation FEBS Lett. 2011, 585, 2024-2031
259. Swiercz, R.; Cheng, D.; Kim, D.; Bedford, M. T. Ribosomal protein rpS2 is hypomethylated in PRMT3-deficient mice J. Biol. Chem. 2007, 282, 16917-16923
260. Smith, J. J.; Rucknagel, K. P.; Schierhorn, A.; Tang, J.; Nemeth, A.; Linder, M.; Herschman, H. R.; Wahle, E. Unusual sites of arginine methylation in poly(A)-binding protein II and in vitro methylation by protein arginine methyltransferases PRMT1 and PRMT3 J. Biol. Chem. 1999, 274, 13229-13234
261. Fronz, K.; Otto, S.; Kolbel, K.; Kuhn, U.; Friedrich, H.; Schierhorn, A.; Beck-Sickinger, A. G.; Ostareck-Lederer, A.; Wahle, E. Promiscuous modification of the nuclear poly(A)-binding protein by multiple protein-arginine methyltransferases does not affect the aggregation behavior J. Biol. Chem. 2008, 283, 20408-20420
262. Tavanez, J. P.; Bengoechea, R.; Berciano, M. T.; Lafarga, M.; Carmo-Fonseca, M.; Enguita, F. J. Hsp70 chaperones and type I PRMTs are sequestered at intranuclear inclusions caused by polyalanine expansions in PABPN1 PLoS One 2009, 4, e6418
263. Allali-Hassani, A.; Wasney, G. A.; Siarheyeva, A.; Hajian, T.; Arrowsmith, C. H.; Vedadi, M. Fluorescence-based methods for screening writers and readers of histone methyl marks J. Biomol. Screening 2012, 17, 71-84
264. Lai, Y.; Song, M.; Hakala, K.; Weintraub, S. T.; Shiio, Y. Proteomic dissection of the von Hippel-Lindau (VHL) interactome J. Proteome Res. 2011, 10, 5175-5182
265. Singh, V.; Miranda, T. B.; Jiang, W.; Frankel, A.; Roemer, M. E.; Robb, V. A.; Gutmann, D. H.; Herschman, H. R.; Clarke, S.; Newsham, I. F. DAL-1/4.1B tumor suppressor interacts with protein arginine N-methyltransferase 3 (PRMT3) and inhibits its ability to methylate substrates in vitro and in vivo Oncogene 2004, 23, 7761-7771
266. Takahashi, Y.; Iwai, M.; Kawai, T.; Arakawa, A.; Ito, T.; Sakurai-Yageta, M.; Ito, A.; Goto, A.; Saito, M.; Kasumi, F.; Murakami, Y. Aberrant expression of tumor suppressors CADM1 and 4.1B in invasive lesions of primary breast cancer Breast Cancer 2012, 19, 242-252
267. Alexiou, G. A.; Markoula, S.; Gogou, P.; Kyritsis, A. P. Genetic and molecular alterations in meningiomas Clin. Neurol. Neurosurg. 2011, 113, 261-267
268. Heller, G.; Geradts, J.; Ziegler, B.; Newsham, I.; Filipits, M.; Markis-Ritzinger, E. M.; Kandioler, D.; Berger, W.; Stiglbauer, W.; Depisch, D.; Pirker, R.; Zielinski, C. C.; Zochbauer-Muller, S. Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer Breast Cancer Res. Treat. 2007, 103, 283-291
269. Chen, X.; Niroomand, F.; Liu, Z.; Zankl, A.; Katus, H. A.; Jahn, L.; Tiefenbacher, C. P. Expression of nitric oxide related enzymes in coronary heart disease Basic Res. Cardiol. 2006, 101, 346-353
270. Miyata, S.; Mori, Y.; Tohyama, M. PRMT3 is essential for dendritic spine maturation in rat hippocampal neurons Brain Res. 2010, 1352, 11-20
271. Siarheyeva, A.; Senisterra, G.; Allali-Hassani, A.; Dong, A.; Dobrovetsky, E.; Wasney, G. A.; Chau, I.; Marcellus, R.; Hajian, T.; Liu, F.; Korboukh, I.; Smil, D.; Bolshan, Y.; Min, J.; Wu, H.; Zeng, H.; Loppnau, P.; Poda, G.; Griffin, C.; Aman, A.; Brown, P. J.; Jin, J.; Al-awar, R.; Arrowsmith, C. H.; Schapira, M.; Vedadi, M. An allosteric inhibitor of protein arginine methyltransferase 3 Structure 2012, 20, 1425-1435
272. Liu, F.; Li, F.; Ma, A.; Dobrovetsky, E.; Dong, A.; Gao, C.; Korboukh, I.; Liu, J.; Smil, D.; Brown, P. J.; Frye, S. V.; Arrowsmith, C. H.; Schapira, M.; Vedadi, M.; Jin, J. Exploiting an allosteric binding site of PRMT3 yields potent and selective inhibitors J. Med. Chem. 2013, 56, 2110-2124
273. Chen, D.; Ma, H.; Hong, H.; Koh, S. S.; Huang, S. M.; Schurter, B. T.; Aswad, D. W.; Stallcup, M. R. Regulation of transcription by a protein methyltransferase Science 1999, 284, 2174-2177
274. Bauer, U. M.; Daujat, S.; Nielsen, S. J.; Nightingale, K.; Kouzarides, T. Methylation at arginine 17 of histone H3 is linked to gene activation EMBO Rep. 2002, 3, 39-44
275. Yadav, N.; Lee, J.; Kim, J.; Shen, J. J.; Hu, M. C. T.; Aldaz, C. M.; Bedford, M. T. Specific protein methylation defects and gene expression perturbations in coactivator-associated arginine methyltransferase 1-deficient mice Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 6464-6468
276. Cheng, D. H.; Cote, J.; Shaaban, S.; Bedford, M. T. The arginine methyltransferase CARM1 regulates the coupling of transcription and mRNA processing Mol. Cell 2007, 25, 71-83
277. El Messaoudi, S.; Fabbrizio, E.; Rodriguez, C.; Chuchana, P.; Fauquier, L.; Cheng, D. H.; Theillet, C.; Vandel, L.; Bedford, M. T.; Sardet, C. Coactivator-associated arginine methyltransferase 1 (CARM1) is a positive regulator of the Cyclin E1 gene Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 13351-13356
278. Lee, Y. H.; Stallcup, M. R. Roles of protein arginine methylation in DNA damage signaling pathways Is CARM1 a life-or-death decision point? Cell Cycle 2011, 10, 1343-1344
279. Fujiwara, T.; Mori, Y.; Chu, D. L.; Koyama, Y.; Miyata, S.; Tanaka, H.; Yachi, K.; Kubo, T.; Yoshikawa, H.; Tohyama, M. CARM1 regulates proliferation of PC12 cells by methylating HuD Mol. Cell. Biol. 2006, 26, 2273-2285
280. Li, H. W.; Park, S. M.; Kilburn, B.; Jelinek, M. A.; Henschen-Edman, A.; Aswad, D. W.; Stallcup, M. R.; Laird-Offringa, I. A. Lipopolysaccharide-induced methylation of HuR, an mRNA-stabilizing protein, by CARM1 J. Biol. Chem. 2002, 277, 44623-44630
281. Xu, W.; Chen, H. W.; Du, K. Y.; Asahara, H.; Tini, M.; Emerson, B. M.; Montminy, M.; Evans, R. M. A transcriptional switch mediated by cofactor methylation Science 2001, 294, 2507-2511
282. Chevillard-Briet, M.; Trouche, D.; Vandel, L. Control of CBP co-activating activity by arginine methylation EMBO J. 2002, 21, 5457-5466
283. Hong, H.; Kao, C.; Jeng, M. H.; Eble, J. N.; Koch, M. O.; Gardner, T. A.; Zhang, S.; Li, L.; Pan, C. X.; Hu, Z.; MacLennan, G. T.; Cheng, L. Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status Cancer 2004, 101, 83-89
284. Majumder, S.; Liu, Y.; Ford, O. H., III; Mohler, J. L.; Whang, Y. E. Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability Prostate 2006, 66, 1292-1301
285. Huynh, T.; Chen, Z.; Pang, S. H.; Geng, J. P.; Bandiera, T.; Bindi, S.; Vianello, P.; Roletto, F.; Thieffine, S.; Galvani, A.; Vaccaro, W.; Poss, M. A.; Trainor, G. L.; Lorenzi, M. V.; Gottardis, M.; Jayaraman, L.; Purandare, A. V. Optimization of pyrazole inhibitors of coactivator associated arginine methyltransferase 1 (CARM1) Bioorg. Med. Chem. Lett. 2009, 19, 2924-2927
286. Purandare, A. V.; Chen, Z.; Huynh, T.; Pang, S.; Geng, J.; Vaccaro, W.; Poss, M. A.; Oconnell, J.; Nowak, K.; Jayaraman, L. Pyrazole inhibitors of coactivator associated arginine methyltransferase 1 (CARM1) Bioorg. Med. Chem. Lett. 2008, 18, 4438-4441
287. Wan, H. H.; Huynh, T.; Pang, S. H.; Geng, J. P.; Vaccaro, W.; Poss, M. A.; Trainor, G. L.; Lorenzi, M. V.; Gottardis, M.; Jayaraman, L.; Purandare, A. V. Benzo[ d ]imidazole inhibitors of coactivator associated arginine methyltransferase 1 (CARM1)-hit to lead studies Bioorg. Med. Chem. Lett. 2009, 19, 5063-5066
288. Therrien, E.; Larouche, G.; Manku, S.; Allan, M.; Nguyen, N.; Styhler, S.; Robert, M. F.; Goulet, A. C.; Besterman, J. M.; Nguyen, H.; Wahhab, A. 1,2-Diamines as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1) Bioorg. Med. Chem. Lett. 2009, 19, 6725-6732
289. Allan, M.; Manku, S.; Therrien, E.; Nguyen, N.; Styhler, S.; Robert, M. F.; Goulet, A. C.; Petschner, A. J.; Rahil, G.; MacLeod, A. R.; Deziel, R.; Besterman, J. M.; Nguyen, H.; Wahhab, A. N -Benzyl-1-heteroaryl-3-(trifluoromethyl)-1 H -pyrazole-5-carboxamides as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1) Bioorg. Med. Chem. Lett. 2009, 19, 1218-1223
290. Selvi, B. R.; Batta, K.; Kishore, A. H.; Mantelingu, K.; Varier, R. A.; Balasubramanyam, K.; Pradhan, S. K.; Dasgupta, D.; Sriram, S.; Agrawal, S.; Kundu, T. K. Identification of a novel inhibitor of coactivator-associated arginine methyltransferase 1 (CARM1)-mediated methylation of histone H3 Arg-17 J. Biol. Chem. 2010, 285, 7143-7152